vs
NATIONAL PRESTO INDUSTRIES INC（NPK）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是NATIONAL PRESTO INDUSTRIES INC的1.3倍（$219.9M vs $164.0M），NATIONAL PRESTO INDUSTRIES INC同比增速更快（21.7% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $12.4M），过去两年NATIONAL PRESTO INDUSTRIES INC的营收复合增速更高（46.3% vs 8.0%）
National Presto Industries创始于1905年，总部位于美国威斯康星州欧克莱尔，历经多次更名后于1953年确定现用名。该公司最初生产商用及后续家用压力锅，自1939年起推出小型家用烹饪电器，1969年在纽约证券交易所上市。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
NPK vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$164.0M
营收增速更快
NPK
高出19.8%
2.0%
自由现金流更多
OFIX
多$4.4M
$12.4M
两年增速更快
NPK
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.0M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 16.9% | 71.1% |
| 营业利润率 | 11.4% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 21.7% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NPKOFIX
| Q4 25 | $164.0M | $219.9M | ||
| Q3 25 | $115.5M | $205.6M | ||
| Q2 25 | $120.4M | $203.1M | ||
| Q1 25 | $103.6M | $193.6M | ||
| Q4 24 | $134.7M | $215.7M | ||
| Q3 24 | $91.8M | $196.6M | ||
| Q2 24 | $85.1M | $198.6M | ||
| Q1 24 | $76.7M | $188.6M |
净利润NPKOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $5.3M | $-22.8M | ||
| Q2 25 | $5.2M | $-14.1M | ||
| Q1 25 | $7.6M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $8.1M | $-27.4M | ||
| Q2 24 | $6.1M | $-33.4M | ||
| Q1 24 | $6.6M | $-36.0M |
毛利率NPKOFIX
| Q4 25 | 16.9% | 71.1% | ||
| Q3 25 | 13.9% | 72.2% | ||
| Q2 25 | 15.4% | 68.7% | ||
| Q1 25 | 17.5% | 62.8% | ||
| Q4 24 | 24.3% | 69.0% | ||
| Q3 24 | 18.8% | 68.7% | ||
| Q2 24 | 17.3% | 67.8% | ||
| Q1 24 | 18.1% | 67.5% |
营业利润率NPKOFIX
| Q4 25 | 11.4% | 0.2% | ||
| Q3 25 | 5.6% | -8.3% | ||
| Q2 25 | 5.1% | -7.9% | ||
| Q1 25 | 8.8% | -25.2% | ||
| Q4 24 | 17.3% | -5.3% | ||
| Q3 24 | 10.0% | -9.6% | ||
| Q2 24 | 7.5% | -12.5% | ||
| Q1 24 | 8.2% | -15.6% |
净利率NPKOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 4.6% | -11.1% | ||
| Q2 25 | 4.3% | -6.9% | ||
| Q1 25 | 7.3% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 8.8% | -13.9% | ||
| Q2 24 | 7.1% | -16.8% | ||
| Q1 24 | 8.6% | -19.1% |
每股收益（稀释后）NPKOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.8M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $395.1M | $450.0M |
| 总资产 | $500.7M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NPKOFIX
| Q4 25 | $3.8M | $82.0M | ||
| Q3 25 | $4.6M | $62.9M | ||
| Q2 25 | $4.8M | $65.6M | ||
| Q1 25 | $5.5M | $58.0M | ||
| Q4 24 | $22.7M | $83.2M | ||
| Q3 24 | $33.2M | $30.1M | ||
| Q2 24 | $53.4M | $26.4M | ||
| Q1 24 | $87.9M | $27.0M |
总债务NPKOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益NPKOFIX
| Q4 25 | $395.1M | $450.0M | ||
| Q3 25 | $379.8M | $442.5M | ||
| Q2 25 | $374.1M | $458.3M | ||
| Q1 25 | $368.6M | $458.3M | ||
| Q4 24 | $367.6M | $503.1M | ||
| Q3 24 | $346.6M | $525.9M | ||
| Q2 24 | $338.1M | $546.0M | ||
| Q1 24 | $331.6M | $570.3M |
总资产NPKOFIX
| Q4 25 | $500.7M | $850.6M | ||
| Q3 25 | $503.8M | $832.6M | ||
| Q2 25 | $471.9M | $837.2M | ||
| Q1 25 | $455.3M | $823.1M | ||
| Q4 24 | $453.4M | $893.3M | ||
| Q3 24 | $428.9M | $867.9M | ||
| Q2 24 | $418.1M | $882.0M | ||
| Q1 24 | $417.5M | $906.0M |
负债/权益比NPKOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $12.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 7.6% | 7.6% |
| 资本支出强度资本支出/营收 | 0.9% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流NPKOFIX
| Q4 25 | $13.9M | $27.7M | ||
| Q3 25 | $-24.6M | $12.4M | ||
| Q2 25 | $-10.9M | $11.6M | ||
| Q1 25 | $12.5M | $-18.4M | ||
| Q4 24 | $-7.6M | $23.7M | ||
| Q3 24 | $-17.5M | $11.7M | ||
| Q2 24 | $-33.9M | $9.0M | ||
| Q1 24 | $5.6M | $-18.6M |
自由现金流NPKOFIX
| Q4 25 | $12.4M | $16.8M | ||
| Q3 25 | $-24.7M | $2.5M | ||
| Q2 25 | $-13.4M | $4.5M | ||
| Q1 25 | $-10.5M | $-25.1M | ||
| Q4 24 | $-11.3M | $15.2M | ||
| Q3 24 | $-20.3M | $6.3M | ||
| Q2 24 | $-34.5M | $-360.0K | ||
| Q1 24 | $5.2M | $-29.1M |
自由现金流率NPKOFIX
| Q4 25 | 7.6% | 7.6% | ||
| Q3 25 | -21.4% | 1.2% | ||
| Q2 25 | -11.1% | 2.2% | ||
| Q1 25 | -10.2% | -13.0% | ||
| Q4 24 | -8.4% | 7.0% | ||
| Q3 24 | -22.1% | 3.2% | ||
| Q2 24 | -40.6% | -0.2% | ||
| Q1 24 | 6.7% | -15.4% |
资本支出强度NPKOFIX
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 0.1% | 4.8% | ||
| Q2 25 | 2.0% | 3.5% | ||
| Q1 25 | 22.2% | 3.5% | ||
| Q4 24 | 2.7% | 4.0% | ||
| Q3 24 | 3.1% | 2.7% | ||
| Q2 24 | 0.8% | 4.7% | ||
| Q1 24 | 0.5% | 5.6% |
现金转化率NPKOFIX
| Q4 25 | — | — | ||
| Q3 25 | -4.63× | — | ||
| Q2 25 | -2.12× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.16× | — | ||
| Q2 24 | -5.58× | — | ||
| Q1 24 | 0.85× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NPK
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
